Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
Recently, the superiority of atezolizumab plus bevacizumab (AteBeva) over sorafenib was proven in the IMbrave150 trial, and AteBeva became the first-line systemic treatment for untreated, unresectable hepatocellular carcinoma (HCC). While the results are encouraging, more than half of patients with...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Korean Liver Cancer Association
2023-03-01
|
| シリーズ: | Journal of Liver Cancer |
| 主題: | |
| オンライン･アクセス: | http://e-jlc.org/upload/pdf/jlc-2023-02-27.pdf |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|